L3VLUP
ProSign in

ZBH · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ZBHJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ZBH
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterZBHJNJ
Q3 202021 holders, $5.3bn30 holders, $26.2bn
Q4 202022 holders, $6.0bn32 holders, $26.6bn
Q1 202122 holders, $5.5bn31 holders, $25.3bn
Q2 202123 holders, $5.6bn37 holders, $25.6bn
Q3 202123 holders, $4.4bn40 holders, $24.1bn
Q4 202120 holders, $3.4bn33 holders, $25.2bn
Q1 202217 holders, $3.4bn35 holders, $28.2bn
Q2 202216 holders, $3.1bn33 holders, $26.9bn
Q3 202219 holders, $3.7bn36 holders, $25.4bn
Q4 202220 holders, $4.6bn35 holders, $27.6bn
Q1 202326 holders, $4.7bn42 holders, $24.5bn
Q2 202323 holders, $5.1bn38 holders, $25.0bn
Q3 202327 holders, $4.0bn37 holders, $18.9bn
Q4 202321 holders, $4.3bn31 holders, $19.0bn
Q1 202419 holders, $5.7bn32 holders, $19.7bn
Q2 202417 holders, $4.5bn35 holders, $20.4bn
Q3 202415 holders, $4.3bn28 holders, $22.3bn
Q4 202417 holders, $4.8bn37 holders, $20.4bn
Q1 202517 holders, $5.1bn32 holders, $20.5bn
Q2 202512 holders, $4.5bn31 holders, $18.4bn
Q3 202512 holders, $4.9bn32 holders, $23.7bn
Q4 20258 holders, $4.9bn29 holders, $27.8bn
Q1 20268 holders, $4.2bn34 holders, $35.6bn
Q2 202612 holders, $4.3bn33 holders, $39.1bn
ZBH

Zimmer Biomet Holdings Inc

Holders
12
Reported value
$4.3bn
Buyers
22
Sellers
10

Breadth +12 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ZBH (5)

ExodusPoint Capital Management LP, Harris Associates LP, Moore Capital Management LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC

Only JNJ (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →